Bilukha Oleg, Messonnier Nancy, Fischer Marc
Meningitis and Vaccine Preventable Diseases Branch, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Pediatr Infect Dis J. 2007 May;26(5):371-6. doi: 10.1097/01.inf.0000259996.95965.ef.
In January 2005, Food and Drug Administration licensed a new tetravalent (serogroups A, C, Y, W-135) meningococcal conjugate vaccine ([MCV4] Menactra) for use in persons 11-55 years of age. In February 2005, CDC's Advisory Committee on Immunization Practices (ACIP) recommended routine vaccination of adolescents and college freshmen living in dormitories with MCV4. The manufacturer started shipments of MCV4 in March 2005. MCV4 should become a key addition to existing meningococcal disease prevention measures.
2005年1月，美国食品药品监督管理局批准了一种新的四价（A、C、Y、W-135血清群）脑膜炎球菌结合疫苗（[MCV4] Menactra），用于11至55岁人群。2005年2月，美国疾病控制与预防中心免疫实践咨询委员会（ACIP）建议对青少年和居住在宿舍的大学新生进行MCV4常规疫苗接种。制造商于2005年3月开始运送MCV4。MCV4应成为现有脑膜炎球菌疾病预防措施的一项重要补充。
